ReviewOncology reviews2017
Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.
Review in Oncology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Article
- PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors.Journal of the American Heart Association · 2025Observational
- Artificial intelligence: Applications in cardio-oncology and potential impact on racial disparities.American heart journal plus : cardiology research and practice · 2024Article
- Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The Role of Nursing in the Delivery of Cardio-Oncology.Current treatment options in oncology · 2024Article
- A comprehensive pediatric cardio-oncology program: a single institution approach to cardiovascular care for pediatric patients with cancer and childhood cancer survivors.Cardio-oncology (London, England) · 2024Review
- Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology.Cardio-oncology (London, England) · 2023Article
- Developing a Clinical Cardio-Oncology Program and the Building Blocks for Success:JACC. CardioOncology · 2023Review
- Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients.European heart journal. Digital health · 2023Article
- Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.European journal of cancer (Oxford, England : 1990) · 2023Article
- Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design.Cardio-oncology (London, England) · 2023Article
- Training and Career Development in Cardio-Oncology Translational and Implementation Science.Heart failure clinics · 2022Review
- Cardio-Oncology Care Delivered in the Non-academic Environment.Current treatment options in oncology · 2022Review
- Personalizing Heart Failure Care to the Patient With Cancer.Current heart failure reports · 2022Review
- Cardio oncology: Digital innovations, precision medicine and health equity.Frontiers in cardiovascular medicine · 2022Review
- Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building.Current oncology reports · 2021Review
- Anti-cancer therapy made easier: a 25-year update.Internal medicine journal · 2021Review
- Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology.Oncology reviews · 2021Article
- Anthracycline-induced cardiotoxicity: A case report and review of literature.World journal of cardiology · 2021Article
- Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital.Cardio-oncology (London, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardio-oncology is a multidisciplinary field focusing on the management and prevention of cardiovascular complications in cancer patients and survivors. While the initial focus of this specialty was on heart failure associated with anthracycline use, novel anticancer agents are increasingly utilized and are associated with many other cardiotoxicities including hypertension, arrhythmias and vascular disease. Since its inception, the field has developed at a rapid pace with the establishment of programs at many major academic institutions and community practices. Given the complexities of this patient population, it is important for providers to possess knowledge of not only cardiovascular disease but also cancer subtypes and their specific therapeutics. Developing a cardio-oncology program at a stand-alone cancer center can present unique opportunities and challenges when compared to those affiliated with other institutions including resource allocation, cardiovascular testing availability and provider education. In this review, we present our experiences establishing the cardio-oncology program at Moffitt Cancer Center and provide guidance to those individuals interested in developing a program at a similar independent cancer institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.